FDA Inspection 1198356 — Sunrise Pharmaceutical, Inc.

Sunrise Pharmaceutical, Inc. — FEI 3004813394

The FDA completed an inspection of Sunrise Pharmaceutical, Inc. on Jan 27, 2023 in Rahway, NJ. The inspection was classified NAI (No Action Indicated — no objectionable conditions or practices were found during the inspection). Product area: Drugs.

Inspection details

Classification
No Action Indicated (NAI)
End Date
Jan 27, 2023
Fiscal Year
2023
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Rahway, NJ (United States)

Sources: openFDA, FDA Data Dashboard, FDA.gov. Report a data issue: hello@regdatalab.com.